A carregar...
Autoimmune Thyroid Diseases in Patients Treated with Alemtuzumab for Multiple Sclerosis: An Example of Selective Anti-TSH-Receptor Immune Response
Alemtuzumab, a humanized anti-CD52 monoclonal antibody, is approved for the treatment of active relapsing-remitting multiple sclerosis (MS). Alemtuzumab induces a rapid and prolonged depletion of lymphocytes from the circulation, which results in a profound immuno-suppression status followed by an i...
Na minha lista:
| Publicado no: | Front Endocrinol (Lausanne) |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5626941/ https://ncbi.nlm.nih.gov/pubmed/29033895 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2017.00254 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|